AIDS Meds: Founded & Operated by People with HIVPOZ logo
Back to home » Treatment News » Top Stories

emailrssprint

Psychiatric Disorders Make HIV Treatment Costly

November 29, 2006

(Reuters Health) - Neuropsychiatric disorders (NPD) add substantially to the cost of treatment of HIV-infected patients, according to a report in the October 24th issue of AIDS.

The prevalence of HIV-associated neuropsychiatric disorders continues to rise during the era of highly active antiretroviral therapy (HAART), the authors explain, but few studies have examined the cost trends associated with these disorders.

Dr. Christopher Power from University of Alberta, Edmonton, Alberta, Canada and colleagues examined whether the high costs of managing NPD increased the costs of care among patients with HIV/AIDS.

Costs per month averaged $916.03 Canadian among HIV-infected patients without any NPD, the authors report, compared with C$1612.52 for patients with cognitive impairment, C$1489.91 for patients with peripheral neuropathy, and C$1361.85 for patients with other NPD.

Patients with two or more neuropsychiatric diagnoses faced significantly higher costs than did patients with only one neuropsychiatric diagnosis, the investigators say.

The additional costs were driven by additional clinic visits, physician visits, and non-antiretroviral drugs, the results indicate, as well as 10-fold higher costs for home care.

Costs were also elevated in the 12 months preceding the diagnosis of NPD, the researchers note, with some of the added costs deriving from increased laboratory costs and specialty physician visits.

Total mean costs per month per patient did not differ between NPD and non-NPD groups in the intervals from 12 to 18 months or from 18 to 24 months prior to the diagnosis of NPD, the report indicates.

"We predict that health costs arising from NPD are likely to rise as the use of HAART generates a patient population with HIV/AIDS that has extended life expectancy, necessitating health care planning for these costs," the authors write.

"In future studies," the researchers add, "it might be useful to examine a wider range of NPDs together with the impact of other intercurrent illnesses, including other infections, substance abuse, and other health determinants that influence healthcare costs."

AIDS 2006;20:2005-2009.



Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

emailrssprint



[Go to top]



Most Popular Stories

CD4s Predictive of Non-AIDS-Related Health Problems

HIV Immunotherapy Shows Promise

Slim for Summer: Safe and Sane Weight Loss

Hetero Men Also at Risk for Anal HPV

Treatment Failure: Symptoms Matter Too

Interfering with Immune Protein Slows HIV Reproduction


Most Popular Lessons

Herpes Simplex Virus

Syphilis & Neurosyphilis

Shingles

The HIV Life Cycle

Human Papilloma Virus (HPV)

What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Treatment News Archive

May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006


© 2008 Smart + Strong. All Rights Reserved. terms of use and your privacy